Back to Search
Start Over
Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5–11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022
- Source :
- The Journal of Infectious Diseases.
- Publication Year :
- 2023
- Publisher :
- Oxford University Press (OUP), 2023.
-
Abstract
- Multisystem inflammatory syndrome in children (MIS-C) is a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; in the United States, reporting of MIS-C after coronavirus disease 2019 (COVID-19) vaccination is required for vaccine safety monitoring. Pfizer-BioNTech COVID-19 vaccine was authorized for children aged 5−11 years on 29 October 2021. Covering a period when approximately 7 million children received vaccine, surveillance for MIS-C ≤ 90 days postvaccination using passive systems identified 58 children with MIS-C and laboratory evidence of past/recent SARS-CoV-2 infection, and 4 without evidence. During a period with extensive SARS-CoV-2 circulation, MIS-C illness in children after COVID-19 vaccination who lacked evidence of SARS-CoV-2 infection was rare (
- Subjects :
- Infectious Diseases
Immunology and Allergy
Subjects
Details
- ISSN :
- 15376613 and 00221899
- Database :
- OpenAIRE
- Journal :
- The Journal of Infectious Diseases
- Accession number :
- edsair.doi...........c0bd68914925dc192d4fc5ce5a723ac6